Pfizer (PFE)
NYSE:PFE

Pfizer (PFE) Stock Forecast & Price Target

22,377 Followers
See the Price Targets and Ratings of:

PFE Analyst Ratings

Moderate Buy
12Ratings
5 Buy
7 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Pfizer
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PFE Stock 12 Months Forecast

Average Price Target

$52.00
▲(5.35% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is $52.00 with a high forecast of $60.00 and a low forecast of $44.00. The average price target represents a 5.35% change from the last price of $49.36.
Highest Price Target$60.00Average Price Target$52.00Lowest Price Target$44.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
BMO Capital
$60.00
Buy
21.56%
Upside
Reiterated
Pfizer (PFE) PT Lowered to $60 at BMO CapitalBMO Capital analyst Evan David Seigerman lowered the price target on Pfizer (NYSE: PFE) to $60.00 (from $65.00) while maintaining a Outperform rating.
Berenberg Bank
$44.00
Hold
-10.86%
Downside
Reiterated
Berenberg Bank Remains a Hold on Pfizer (PFE)
Truist Financial
$64.00
Buy
29.66%
Upside
Reiterated
Pfizer (PFE) PT Raised to $64 at Truist Securities; Incrementally more positive following resultsTruist Securities analyst Robyn Karnauskas raised the price target on Pfizer (NYSE: PFE) to $64.00 (from $62.00) while maintaining a Buy rating following the results.
Cowen & Co.
$60.00
Buy
21.56%
Upside
Reiterated
Pfizer (PFE) Earnings Growth Underappreciated - Cantor FitzgeraldIn addition, Cowen analyst Steve Scala maintained an Outperform rating and $60 price target on Pfizer, telling investors in a note that "Q2 sales beat expectations as did EPS. Guidance for 2022 revenue was reiterated and EPS raised at the low end. Comirnaty and Paxlovid 2022 guidance was reiterated though Q2 sales beat our estimate."
Cantor Fitzgerald
$75.00
Buy
51.94%
Upside
Reiterated
Pfizer (PFE) Earnings Growth Underappreciated - Cantor Fitzgerald"We think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital, are all underappreciated. Therefore, we believe multiple expansion and upward earnings estimate revisions should drive PFE shares higher," wrote Chen.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

PFE Financial Forecast

PFE Earnings Forecast
Next quarter’s earnings estimate for PFE is $1.07 with a range of $0.96 to $1.29. The previous quarter’s EPS was $1.78. PFE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.49% of the time in the same period. In the last calendar year PFE has Outperformed its overall industry.
Next quarter’s earnings estimate for PFE is $1.07 with a range of $0.96 to $1.29. The previous quarter’s EPS was $1.78. PFE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.49% of the time in the same period. In the last calendar year PFE has Outperformed its overall industry.
PFE Sales Forecast
Next quarter’s sales forecast for PFE is $24.32B with a range of $22.91B to $26.02B. The previous quarter’s sales results were $22.64B. PFE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year PFE has Outperformed its overall industry.
Next quarter’s sales forecast for PFE is $24.32B with a range of $22.91B to $26.02B. The previous quarter’s sales results were $22.64B. PFE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year PFE has Outperformed its overall industry.
PFE Analyst Recommendation Trends
In the current month, PFE has received 4 Buy ratings 5 Hold ratings, and 0 Sell ratings. The PFE average analyst price target in the past 3 months is $52.00
In the current month, PFE has received 4 Buy ratings 5 Hold ratings, and 0 Sell ratings. The PFE average analyst price target in the past 3 months is $52.00

PFE Stock Forecast FAQ

What is PFE’s average 12-month price target, according to analysts?
Based on analyst ratings, Pfizer’s 12-month average price target is $52.00.
    What is PFE’s upside potential, based on the analysts’ average price target?
    Pfizer has 5.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PFE a Buy, Sell or Hold?
          Pfizer has a conensus rating of Moderate Buy which is based on 5 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Pfizer’s price target?
            The average price target for Pfizer is $52.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $60.00 ,the lowest forecast is $44.00. The average price target represents 5.35% Increase from the current price of $49.36.
              What do analysts say about Pfizer?
              Pfizer’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis